Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Calcif Tissue Int 2016;99: 489-499. PMID: 27395059
Time- dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats. Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL, Aguirre JI, Wronski TJ, Buntich S, Afshari CA, Pyrah I, Nioi P, and Waite Boyce R. Bone 2016;84:148-159. PMID: 26721737
One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption. Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G. J Bone Miner Res 2017;32:23-33. PMID: 27894941
Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster J-Y, Singer A, Wang C, Wagman RB, Cummings SR. J Clin Endocrinol Metab 2016;101:3163-3170. PMID: 27270237
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study. Reg Toxicol Pharmacol 2016;81:1-11. PMID: 27569204
Fracture healing physiology and the quest for therapies for delayed healing and nonunion. Kostenuik P and Mirza FM. J Orthop Res 2017;35:213-223. PMID: 27743449
Denosumab reduced bone remodeling, eroded surface, and erosion depth in cortical bone of iliac crest biopsies from postmenopausal women in the FREEDOM trial. Chapurlat R, Portero-Muzy N, Roux J-P, Horlait S, Dempster D, Wang A, Wagman R, Chavassieux P. J Bone Miner Res 32(Suppl. 1):S38.
Abaloparatide, a selective PTH1 receptor agonist, reversed bone loss and improved trabecular architecture in orchiectomized rats. Chandler H, Mullarkey T, Stewart R, Hattersley G. J Bone Miner Res 32(Suppl. 1):S275.
Safety observations with 3 years of denosumab exposure: comparisons between subjects who received denosumab during the randomized FREEDOM trial and subjects who crossed over to denosumab during the FREEDOM Extension. Watts NB, Brown JP, Papapoulos S, Lewiecki EM, Kendler DL, Dakin P, Wagman RB, Wang A, Daizadeh NS, Smith S, Bone HG. J Bone Miner Res 2016;32:1481-1485. PMID: 28277603
Abaloparatide, an osteoanabolic PTHrP analog, increased bone mineral density in rabbits with glucocorticoid induced osteopenia. Chandler H, Pierce A, Brown J, Ominsky M, Hattersley G. Arthritis Rheum 2017;69(Suppl. 10): Abstract 1937.
One year of abaloparatide, a selective peptide activator or the PTH1 receptor, increased bone mass and strength in ovariectomized rats. Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G. Bone 2017;95:143-150. PMID: 27894941
Abaloparatide, a novel PTHrP analog, increased bone mass and density at cortical and trabecular sites in an orchiectomized rat model of male osteoporosis. Chandler H, Hattersley G. Arthritis Rheum 2017;69(Suppl. 10): Abstract 59.
Abaloparatide increased bone mass in a rabbit glucocorticoid-induced osteopenia model. Chandler H, Pierce A, Brown J, Ominsky M, Hattersley G. J Bone Miner Res 32(Suppl. 1): S385.
Abaloparatide-SC improved cortical bridging and increased callus mass and strength in a rat closed femur fracture model. Chandler H, Pierce A, Brown J, Ominsky M, Hattersley G. J Bone Miner Res 32(Suppl. 1): S165.
Why is hypercholesterolemia so prevalent? A view from evolutionary medicine. Laufs U, Dent R, Kostenuik PJ, Toth PP, Catapano AL, Chapman MJ. Eur Heart J 2019;40(33):2825-2830. PMID: 30169643
Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption. Doyle N, Varela A, Haile S, Guldberg R, Kostenuik PJ, Ominsky MS, Smith SY, Hattersley G. Osteoporosis Int 2018;29:685-697. PMID: 29260289
Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia. Chandler H, Brooks DJ, Hattersley G, Bouxsein ML, and Lanske B. Osteoporos Int 2019;30:1607-1616. PMID: 31053927
Effects of abaloparatide and teriparatide on bone resorption and bone formation in female mice. Arlt H, Mullarkey T, Hu D, Baron R, Ominsky MS, Mitlak B, Lanske B, Besschetnova T. Bone Rep 2020;13:100291. PMID: 32637467
Abaloparatide treatment increases bone density without increasing bone resorption in a rat model of hindlimb unloading. Teguh D, Nustad JL, Craven AE, Brooks DJ, Arlt H, Hu D, Baron R, Lanske B, Bouxsein, ML. Bone 2021;144:115801. PMID: 33338664
The effect of discontinuing denosumab in patients with rheumatoid arthritis treated with glucocorticoids. Saag KG, McDermott MT, Adachi J, Lems W, Lane NE, Geusens P, Stad RK, Chen L, Huang S, Dore R, Cohen S. Arthritis Rheumatol 2022;74(4):604-611. PMID: 34535967